Sanofi-Aventis Picks Two To Head U.S.: Rothwell, Soriot On Management Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.
You may also be interested in...
Sanofi-Aventis Nominates Le Fur For CEO Post In 2007
Under the proposal, Sanofi-Aventis CEO Dehecq will remain as chairman for three years to ensure a smooth transition.
Sanofi-Aventis Nominates Le Fur For CEO Post In 2007
Under the proposal, Sanofi-Aventis CEO Dehecq will remain as chairman for three years to ensure a smooth transition.
Former Aventis Exec Hofstaetter Finds A New Home At Wyeth
Thomas Hofstaetter is responsible for business and corporate development as a senior VP, reporting to Wyeth CEO Robert Essner and Pharmaceuticals President Bernard Poussot.